Traders should focus on upcoming catalysts: DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 data. Cash runway into 2027 provides a buffer. No guidance change; stock likely to trade on pipeline news rather than financials.
KOD drugs
KOD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $41.01entry
- T+1 · 6mo ago −2.83%α −3.06% · $39.85
- T+5 · 6mo ago −5.63%α −7.10% · $38.70
- T+20 · 5mo ago −24.29%α −24.31% · $31.05
- T+60 · 3mo ago +4.58%α −0.26% · $42.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in line with consensus of $0.93. The pre-revenue biotech highlighted positive GLOW2 data and expects DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 readouts. Cash of $169.5M is expected to fund operations into 2027.
Key Financial Metrics
Key Facts
- Net loss $58.2M, or $0.94 per share, vs $57.5M ($1.09) in Q1 2025
- Cash and cash equivalents $169.5M, down from $209.9M at Dec 31, 2025
- R&D expenses $48.5M vs $43.6M YoY, driven by increased clinical activities
- Zenkuda BLA submission planned; DAYBREAK topline data expected Sep 2026
- KSI-101 Phase 3 PEAK topline expected Q4 2026, PINNACLE Q2 2027
- No revenue; company is pre-commercial
Financial Impact
Net loss per share $0.94 vs consensus $0.93, essentially in line. Cash burn ~$40M in the quarter.
Risk Factors
- Potential delays or failures in Phase 3 trials (DAYBREAK, PEAK, PINNACLE)
- Cash burn rate may require additional financing before readouts
- BLA submission and approval risks for Zenkuda
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-211811 |
| Document: kod-20260507.htm | 0001193125-26-211811 |
| Document: 0001193125-26-211811-index-headers.html | 0001193125-26-211811 |
| Document: 0001193125-26-211811-index.html | 0001193125-26-211811 |
| Document: 0001193125-26-211811.txt | 0001193125-26-211811 |
| 8-K Data (Synthetic) | 0001193125-26-211811 |
Track record
13 reports on KOD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $100.73 +4.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $100.73 +8.01% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $100.73 −9.41% settles Dec 14
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $100.73 −5.95% settles Dec 8
- Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $100.73 −14.83% settles Nov 18
- Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
- Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $100.73 +12.02% ▼ −0.36% −0.32% vs SPY
- Aug 13, 202613w ago 8-K Neutral 4/10 No price data
- Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $100.73 +143.60% ▼ −19.85% −17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers